CN Patent

CN106117214A — 依鲁替尼新晶型及其制备方法

Assigned to SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co Ltd · Expires 2016-11-16 · 10y expired

What this patent protects

本发明提供一种依鲁替尼新晶型及其制备方法。具体地，本发明提供了依鲁替尼晶型III及其制备方法。本发明所提供的制备方法制得的依鲁替尼晶型III具有良好的热稳定性，常规条件下储存稳定，适合工业化应用。

USPTO Abstract

本发明提供一种依鲁替尼新晶型及其制备方法。具体地，本发明提供了依鲁替尼晶型III及其制备方法。本发明所提供的制备方法制得的依鲁替尼晶型III具有良好的热稳定性，常规条件下储存稳定，适合工业化应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN106117214A
Jurisdiction
CN
Classification
—
Expires
2016-11-16
Drug substance claim
No
Drug product claim
No
Assignee
SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.